Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)


Section Navigation
			
			CDC Home








ACIP: Guidance for Health Economics Studies						Print
																Related Pages
										**These procedures should be followed for economic analyses to be presented to an ACIP Work Group or to the ACIP, effective as of the ACIP meeting of October 23-24, 2019.**
Cost-effectiveness and other types of economic analyses are frequently presented during meetings of ACIP Work Groups (WGs) and the ACIP. The *Guidance for Health Economics Studies Presented to the ACIP, 2019 Update* (Guidance) was developed to ensure that economic data presented to the WGs and to the ACIP are uniform in presentation, understandable, and of the highest quality. The Guidance mandates a technical review of any economic study that is being considered for presentation. Economic study materials that are being submitted for review must include two items: (1) a document or report that describes the methods and results of the study, and (2) a slide set and/or other presentation materials.
A detailed description of the materials to be presented, the timeline for submission, and the review process may be found in: ACIP Guidance for Health Economics Studies, 2019 Update [21 pages]
The original, 2008 version of the Guidance available here: ACIP Guidance for Health Economics Studies [9 pages]
A template for preparation of presentation slides may be found in: ACIP Guidance for Presentation Slides for Health Economics Studies [18 slides]The report and presentation materials must be submitted to the relevant ACIP WG Chair and CDC Lead staff person no later than 8 weeks before the presentation is to be made at an ACIP WG meeting.
Selected* publications of health economic modeling studiesPublished cost effective analysis (CEA) studies
Vaccine
MMWR publication date
Vaccine recommendations published in MMWR
Economic model publicationsPneumococcal
September 2022
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United StatesHepatitis B
April 2022
Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among AdultsZoster (Shingles)
January 2022
Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 YearsDengue
December 2021
Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021
Cost-effectiveness of dengue vaccination in Puerto RicoTdap
January 2020
Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019
Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United StatesPneumococcal
November 2019
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization programCost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditionsHPV
August 2019
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices
Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United StatesCost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission modelJapanese Encephalitis
July 2019
Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices
Comparative economic analysis of strategies for Japanese encephalitis vaccination of U.S. travelersZoster (Shingles)
January 2018
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National RecommendationsProjected risks and health benefits of vaccination against herpes zoster and related complications in US adultsHPV
December 2016
Use of a 2-Dose Schedule for Human Papillomavirus Vaccination — Updated Recommendations of the Advisory Committee on Immunization Practices
Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness AnalysisHPV
March 2015
Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
Health and Economic Impact of Switching From a 4-Valent to a 9-Valent HPV Vaccination Program in the United StatesThe impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission modelImpact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV VaccineMeningococcal
March 2013
Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MCV vaccination in the presence of vaccine-associated Guillain–Barré Syndrome risk: A decision analysis approachPneumococcal
October 2012
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditionsHPV
December 2011
Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males — Advisory Committee on Immunization Practices (ACIP), 2011
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesThe cost-effectiveness of male HPV vaccination in the United StatesTdap
October 2011
Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact with an Infant Aged <12 Months — Advisory Committee on Immunization Practices (ACIP), 2011
Pregnancy Dose Tdap and Postpartum Cocooning to Prevent Infant Pertussis: A Decision AnalysisMeningococcal
August 2007
Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11–18 Years with Meningococcal Conjugate Vaccine
Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United StatesVaricella
June 2007
Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
An Economic Analysis of the Universal Varicella Vaccination Program in the United StatesCost-effectiveness of a Routine Varicella Vaccination Program for US ChildrenHPV
March 2007
Quadrivalent human papillomavirus vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP)
Cost-effectiveness of Human Papillomavirus Vaccination in the United StatesHepatitis A
May 2006
Prevention of Hepatitis A Through Active or Passive Immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)
Cost-Effectiveness of Routine Childhood Vaccination for Hepatitis A in the United StatesMeningococcal
March 2005
Prevention and Control of Meningococcal Disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)
Vaccinating first-year college students living in dormitories for meningococcal disease: an economic analysisCost-effectiveness of conjugate meningococcal vaccination strategies in the United StatesShould college students be vaccinated against meningococcal disease? A cost-benefit analysis*The table does not include all publications of models presented to ACIP; e.g., industry/sponsor models are not included.Top of Page
							
					
							Last Reviewed:  October 23, 2019						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue